All Updates

All Updates

icon
Filter
Partnerships
PreciseDx and COTA partner to enhance AI-powered precision breast cancer diagnostic
Precision Medicine
May 29, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Precision Medicine

Precision Medicine

May 29, 2024

PreciseDx and COTA partner to enhance AI-powered precision breast cancer diagnostic

Partnerships

  • Precise DX and COTA have partnered with Baptist Health South Florida to assess the performance of PreciseDx's AI-enabled PreciseBreast (PDxBr) test for assessing the risk of invasive breast cancer (IBC) recurrence.

  • The validation assessment will compare PDxBr’s results to traditional pathology reviews and 21-gene assay results. If the validation study is successful, Baptist Health has agreed to offer the test to its patients with IBC to expand access to the product within the oncology sector. The test is claimed to produce results in 48 hours at an 80% lower cost than conventional pathology solutions. 

  • New York-based PreciseDx leverages advanced AI to analyze samples and provide patient-specific risk information. The company's key offerings include the PreciseDx platform, which helps patients and healthcare practitioners understand breast cancer diagnosis and determine personalized treatment plans.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.